Metraipolis › archive › dc_a4d6adeb208c
Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control — Europe PMC PMID:42284551
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42284551
- DOI
- 10.1158/2767-9764.crc-26-0207
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-18T13:57:36.269Z
- SHA-256 of the archived text
7b55a7bda0b14880200d88b664adf32361395781d9e520432e15db71d93d7c42- Stable URL of this page
https://metraipolis.com/documento/dc_a4d6adeb208c
How to cite
Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control — Europe PMC PMID:42284551 — Europe PMC (en), https://europepmc.org/article/MED/42284551 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_a4d6adeb208c (Metraipolis archive dc_a4d6adeb208c, sha256 7b55a7bda0b14880200d88b664adf32361395781d9e520432e15db71d93d7c42)
BibTeX
@misc{dca4d6adeb208c,
title = {Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control — Europe PMC PMID:42284551},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42284551},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_a4d6adeb208c; sha256 7b55a7bda0b14880200d88b664adf32361395781d9e520432e15db71d93d7c42},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42284551. Agents can read the archived copy with the MCP tool read_document.